Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · IEX Real-Time Price · USD
98.24
+0.84 (0.86%)
Jun 24, 2022 4:00 PM EDT - Market closed
0.86%
Market Cap 9.39B
Revenue (ttm) 1.21B
Net Income (ttm) 71.40M
Shares Out 95.58M
EPS (ttm) 0.73
PE Ratio 134.58
Forward PE 43.67
Dividend n/a
Ex-Dividend Date n/a
Volume 800,199
Open 98.40
Previous Close 97.40
Day's Range 95.81 - 99.05
52-Week Range 71.88 - 108.02
Beta 0.70
Analysts Buy
Price Target 114.05 (+16.1%)
Earnings Date Aug 2, 2022

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarbo... [Read more...]

Industry Biotechnology
IPO Date May 23, 1996
CEO Kevin Gorman
Employees 1,100
Stock Exchange NASDAQ
Ticker Symbol NBIX
Full Company Profile

Financial Performance

In 2021, NBIX's revenue was $1.13 billion, an increase of 8.38% compared to the previous year's $1.05 billion. Earnings were $89.60 million, a decrease of -78.00%.

Financial Statements

Analyst Forecast

According to 32 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is 114.05, which is an increase of 16.09% from the latest price.

Price Target
$114.05
(16.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia ...

- Substantial Reductions in Key Hormones and Hormone Precursors Observed After 14 Days of Crinecerfont Treatment in Adolescents with Classic CAH - Two Phase 3 Global Registrational Studies Currently Und...

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

SAN DIEGO , June 8, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time (1:40 p.m.

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala

SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) was honored by the CARES Foundation for its ongoing research and development of novel therapies for patients with cla...

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Moto...

SAN DIEGO , June 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson's disease (PD) demonstrating the impact of OFF episodes, or re...

Neurocrine Biosciences Announces Repurchase of Convertible Notes

SAN DIEGO , May 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) (the "Company" or "Neurocrine Biosciences") today announced that it has entered into separate, privately negotiated t...

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of P...

SAN DIEGO , May 23, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data on the use of INGREZZA® (valbenazine) capsules for the treatment of tardive...

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Hun...

SAN DIEGO, May 12, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valb...

Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

INGREZZA® (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA® (valbenazine) 2022 Net Product Sales Guidance Reiterated at $1.25 - $1.35 Billion SAN DIEGO , May 4, 2022 /PRNewswire/ -...

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

SAN DIEGO , May 3, 2022  /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time (2:20 p.m.

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week

States Across the Country Declare First Week of May (1-7) Tardive Dyskinesia Awareness Week to Raise Awareness of This Burdensome and Often Misunderstood Condition An Estimated 75% of Those with TD Have...

Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter ...

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Hu...

-  Valbenazine Met the Primary Endpoint of Significant (p

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia...

SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory ap...

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living w...

SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients...

Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-...

SAN DIEGO , March 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research at the Amer...

Neurocrine Biosciences to Present at Stifel 2022 CNS Days

SAN DIEGO , March 21, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday, March 28, 2022.

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences: Kevin Gor...

Bear of the Day: Neurocrine Biosciences (NBIX)

Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of $316....

Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations f...

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided fin...

Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results

SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webc...